Genmab A-S

Genmab to unveil Phase III epcoritamab data at ASCO 2026—showcasing 60% ORR in relapsed lymphoma, subcutaneous bispecifics, and future trials for Rinatabart and petosemtamab.

Genmab’s new 5% stake by Orbis Investment signals potential influence on its antibody‑therapy pipeline, boosting investor confidence in its biopharma strategy.

Genmab A/S boosts governance by issuing RSUs and warrants, aligning executives with shareholder value while meeting market‑abuse rules – a transparent move that may drive long‑term growth.

Genmab A/S, a Danish biotech firm, is experiencing market momentum due to its strategic acquisition of Merus and advancements in its antibody-based oncology portfolio, with analysts revising their price targets and the company’s shares surpassing a …

Genmab A/S, a Danish biotech firm, is experiencing a modest surge in its share price, but underlying volatility and rising short interest suggest that investors remain skeptical about the company’s long-term viability and potential for growth.

Genmab’s share price has surged in recent days due to positive clinical trial results for its cancer therapy Epkinly and an anticipated regulatory review of its treatment Darzalex, solidifying the company’s position as a leader in the biopharmaceuti…

Genmab’s stock price has fluctuated significantly in recent days due to global market volatility, raising concerns about the company’s ability to compete with peers and the need for a more robust strategy to mitigate market fluctuations.

Genmab A/S, a biotechnology company, has seen a significant surge in its stock price, surpassing key market benchmarks and ranking third on the Stoxx 600 index.

Genmab’s share capital sees a modest boost due to employee warrant exercises, but the company’s stability and commitment to innovation position it for long-term success.

Genmab A-S, a biotech company, reported a 19% revenue increase and 56% operating profit growth in its second-quarter financial results, despite a decline in its stock price.